Research Studies

We have over 30 enrolling studies. For a complete list of our studies, please contact us

AAA – 1303
The purpose of this research study is to assess the safety and effectiveness of the GORE® EXCLUDER® Conformable AAA Endoprosthesis when used for the treatment of Abdominal Aortic Aneurysms (AAA).   Dr. David Varnagy serves as the Principal Investigator on this W.L.Gore and Associates, Inc. sponsored study. 

AdaptResponse
The purpose of this study is to see if receiving electrical treatment from a Cardiac Resynchronization Therapy (CRT) device with the aCRT programming feature is better than receiving electrical treatment from a CRT device with the standard method of CRT device programming in patients with heart failure. Dr. George Monir serves as the Principal Investigator on this Medtronic-sponsored study.

BEAT HF
The purpose of this research study is to show whether the implantable Barostim Neo® system device is safe and works in people with heart failure to improve patient outcomes. Dr. Nirav Raval serves as the Principal Investigator on this CVRx-sponsored study.

DECAAF II
The purpose of this study is to compare the standard AF catheter ablation procedure with the standard ablation procedure and the delayed enhancement (DE-MRI) guided ablation procedure to determine which ablation procedure is more effective at reducing the chances of reoccurrence of atrial fibrillation.  Dr. George Monir serves as the Principal Investigator on this University of Utah study. 

DIAMOND AF
The purpose of this clinical study is to see whether a medical device called the DiamondTemp Ablation Catheter (also called the DiamondTemp Ablation System) can restore your heart to a normal heart rhythm.  Dr. Usman Siddiqui serves as the Principal Investigator on this Advanced Cardiac Therapeutics, Inc. study.


ECLIPSE
The purpose of this trial is to evaluate orbital atherectomy vessel preparation compared to standard angioplasty prior to placing a stent for the treatment of CAD. The Diamondback 360® Coronary Orbital Atherectomy System (OAS) uses a diamond-coated crown that spins back and forth inside your blocked artery (blood vessel) to sand and reduce the calcium.  Atherectomy is the medical term describing the removal of plaque from the arteries.  The use of the OAS is called orbital atherectomy (OA). Standard angioplasty will allow vessel preparation with any device, except for atherectomy, that has been approved or cleared by the Food and Drug Administration (FDA) for treating CAD. None of the devices used in this trial are experimental. Dr. Rohit Bhatheja serves as the Principal Investigator on this Cardiovascular Systems, Inc. sponsored study.

EVAS II
The goal of this study is to evaluate the safety and effectiveness of the Nellix® System.  The information collected from this study will be used to assess how well patients do when treated with the Nellix System both immediately after the repair of the aneurysm and over the following five (5) years.  Dr. Manuel Perez-Izquierdo serves as the Principal Investigator on this Endologix, Inc. study.

INCREASE 201
The purpose of this research study is to investigate the safety and how well inhaled treprostinil works in subjects with PH associated with ILD or CPFE.  This study will look at your ability to exercise after taking the study drug.  If you choose to participate in this study and meet all the study entry requirements, you will be randomly assigned (by chance; like the flip of a coin) to receive either active study drug (inhaled treprostinil) or placebo.  Half of the subjects participating in this study will receive active study drug (inhaled treprostinil) and the other half will receive placebo (i.e. 50/50).  Neither your study doctor nor you will know whether you are receiving the study drug or placebo. Dr. James Tarver, III serves as the Principal Investigator on this United Therapeutics Corporation sponsored study.

INCREASE 202
The purpose of this research study is to provide or continue to provide inhaled treprostinil to eligible subjects who participated in the RIN-PH-201 study.  The study will also investigate the safety and how well inhaled treprostinil works in subjects with PH associated with ILD or CPFE.  This study will look at your ability to exercise after taking the study drug.  If you choose to participate in this study and meet all the study entry requirements, you and your study doctor will not be told whether you were receiving active inhaled treprostinil or placebo in the RIN-PH-201 study.  All participants in this study will receive active inhaled treprostinil.  Dr. James Tarver, III serves as the Principal Investigator on this United Therapeutics Corporation sponsored study.

ON-X
The On-X Valve is a mechanical heart valve used for valvular replacement of the aortic and mitral valves. The valve is commercially available. Mechanical valves require lifelong anticoagulation therapy. The open portion of the study is the Mitral Valve Replacement arm. This study is intended to define the lowest level of required anticoagulation for the patient post valve implant. Dr. Kevin Accola serves as the Principal Investigator on this Medical Carbon Research Institute-sponsored study.

PLEXA
The purpose of this registry study is to confirm the long-term safety and reliability of the Plexa lead used with a BIOTRONIK ICD or CRT-D. The treatment is standard of care. The only research activity is collecting data related to this.  The study sponsor, BIOTRONIK, will collect long‑term data on the Plexa lead, ICD or CRT-D and health status. The study involves collection and review of data at regular follow-up visits.  The BIOTRONIK Plexa lead is legally marketed in the United States and is not an investigational product.  Dr. Naushad Shaik serves as the Principal Investigator on this BIOTRONIK, Inc. sponsored study.

QP EXCELS
The purpose of this clinical research study is to confirm the safety and effectiveness of the BIOTRONIK Sentus QP lead used with the BIOTRONIK CRT-D device. The study is intended for cases in which the doctor has determined that the patient needs a cardiac resynchronization therapy defibrillator (CRT-D) system. Dr. Naushad Shaik serves as the Principal Investigator on this Biotronik-sponsored study.

RANGER II SFA
The purpose of this research study is to compare the safety and effectiveness of the Ranger™ drug-coated balloon to standard (non-drug coated) balloons for the treatment of your narrowed or blocked vessel.   Dr. Rohit Bhatheja serves as the Principal Investigator on this Boston Scientific Corporation sponsored study.

RECHORD
The purpose of this research study is to show whether an investigational device, called the DS1000, is safe and effective to reduce mitral regurgitation. The DS1000 is a hand-held instrument that is designed to deliver sutures (stitches) to the mitral valve in your heart. Dr. Kevin Accola serves as the Principal Investigator on this NeoChord, Inc. sponsored study.

RELAY PRO A
The purpose of this study is to investigate the safety and effectiveness of the Relay PRO Thoracic Stent-Grafts in subjects with aneurysms and PAUs with the descending thoracic aorta.  Dr. Mark Ranson serves as the Principal Investigator on this Bolton Medical, Inc. sponsored study. 

SOUTHPAW
The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24 in subjects with PH associated with HFpEF.  Dr. James Tarver, III serves as Principal Investigator of this United Therapeutics Corporation sponsored study. 

SOUTHPAW OL
The primary objective of this study is to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed the SOUTHPAW study.  Dr. James Tarver, III serves as Principal Investigator of this United Therapeutics Corporation sponsored study. 

TACTISENSE
The purpose of this research study is to collect information on the safety and effectiveness of the TactiCath SE ablation catheter when it is used to treat atrial fibrillation.  Dr. Usman Siddiqui serves as Principal Investigator of this Abbott sponsored study.